Advancing mAbs to Achieve a Drug-free Sustained HIV Virologic Remission (U01 Clinical Trial Required)

Funding Opportunity RFA-AI-18-022 from the NIH Guide for Grants and Contracts. The Purpose of this Funding Opportunity Announcement is to solicit applications to rapidly implement early clinical trials using native and/or engineered monoclonal antibodies (mAbs) to achieve a drug-free sustained virologic remission in HIV infected individuals.

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-022.html

Source: NIH Funding Opportunities (Notices, PA, RFA) - June 28, 2018 Category: Research Source Type: funding